Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)‘s stock had its “buy” rating reiterated by equities research analysts at Cowen and Company in a report issued on Tuesday.

The analysts wrote, “Analysts Are Bullish on Top Healthcare Picks | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=f8716fc3dc&wpp_id=460231’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Analysts Are Bullish on Top Healthcare Picks”

ICPT has been the topic of several other reports. Wedbush reissued an “outperform” rating and set a $239.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, September 16th. Zacks Investment Research downgraded shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 2nd. Wells Fargo & Co. reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 28th. Leerink Swann reissued a “positive” rating and set a $159.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, October 14th. Finally, Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $200.00 price objective (down from $250.00) on shares of Intercept Pharmaceuticals in a research report on Monday, October 24th. Five analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $177.07.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 113.91 on Tuesday. The stock’s market capitalization is $2.83 billion. The firm has a 50-day moving average of $135.79 and a 200 day moving average of $147.46. Intercept Pharmaceuticals has a 12-month low of $89.76 and a 12-month high of $189.39.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.82) by $0.23. Intercept Pharmaceuticals had a negative net margin of 3,287.95% and a negative return on equity of 66.97%. The company had revenue of $4.70 million for the quarter, compared to the consensus estimate of $4.77 million. During the same period last year, the firm posted ($2.10) EPS. Intercept Pharmaceuticals’s revenue for the quarter was up 1051.1% on a year-over-year basis. Equities analysts forecast that Intercept Pharmaceuticals will post ($15.70) earnings per share for the current fiscal year.

In related news, CEO Mark Pruzanski sold 35,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 20th. The shares were sold at an average price of $165.00, for a total transaction of $5,775,000.00. Following the completion of the transaction, the chief executive officer now owns 579,314 shares of the company’s stock, valued at $95,586,810. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Lisa Bright sold 246 shares of the company’s stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $159.00, for a total transaction of $39,114.00. Following the transaction, the insider now directly owns 18,460 shares of the company’s stock, valued at approximately $2,935,140. The disclosure for this sale can be found here. 9.20% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the company. CENTRAL TRUST Co bought a new position in shares of Intercept Pharmaceuticals during the second quarter valued at approximately $107,000. The Manufacturers Life Insurance Company bought a new position in shares of Intercept Pharmaceuticals during the third quarter valued at approximately $114,000. KBC Group NV raised its position in shares of Intercept Pharmaceuticals by 660.2% in the third quarter. KBC Group NV now owns 897 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 779 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Intercept Pharmaceuticals by 67.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 915 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 370 shares during the period. Finally, Legal & General Group Plc raised its position in shares of Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 52 shares during the period. 80.73% of the stock is owned by hedge funds and other institutional investors.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.